Q-omics provides the consensus-scored NPM1P18 profile across patient tissues and cancer cell-line models. NPM1P18 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NPM1P18 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, NPM1P18 RNA expression shows 9,736 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, LUAD, and GBM as cancer lineages where NPM1P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPM1P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPM1P18 survival associations across molecular data types. NPM1P18 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPM1P18 RNA expression–survival associations across cancer types. High NPM1P18 expression shows unfavorable associations in BLCA, KICH, KIRP and UVM, but favorable associations in KIRC and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NPM1P18 RNA expression.
This table summarizes NPM1P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPM1P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPM1P18 shows higher tumor expression in LUAD, BLCA, HNSC, COAD, READ and PAAD. The LUAD box plot shows higher NPM1P18 RNA expression in tumor versus normal tissue (log2 FC = +0.192, t-test p < 0.001).
This table shows molecular features associated with NPM1P18 in patient tissues and cancer cell lines. In patient samples, NPM1P18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
